Lupin Ltd

Lupin Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lupin Ltd

₹ 1,974 0.26%
23 May 11:06 a.m.
lupin.com BSE: 500257 NSE: LUPIN
About

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

Key Points

Products
Co. is engaged in developing and marketing generic formulations, biotechnology products, and APIs globally. Co. has a significant presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, and Central Nervous system, among other segments, and is a global leader in e Anti-TB and Cephalosporins segments. [1]

Website BSE NSE
  • Market Cap ₹ 90,113 Cr.
  • Current Price ₹ 1,974
  • High / Low ₹ 2,403 / 1,493
  • Stock P/E 22.3
  • Book Value ₹ 532
  • Dividend Yield 0.41 %
  • ROCE 22.1 %
  • ROE 18.0 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has delivered good profit growth of 28.5% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 24.1%

Cons

  • Stock is trading at 3.70 times its book value
  • The company has delivered a poor sales growth of 9.00% over past five years.
  • Company has a low return on equity of 11.2% over last 3 years.
  • Debtor days have increased from 101 to 122 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE 500 BSE Healthcare BSE 100 BSE 200 Nifty 500

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
2,855 2,732 2,829 2,861 2,836 3,496 3,659 4,116 3,396 4,168 4,106 4,208 4,486
2,354 2,444 2,515 2,646 2,574 2,791 2,824 2,898 2,696 2,968 2,991 2,797 2,740
Operating Profit 501 289 314 215 262 705 835 1,217 700 1,200 1,115 1,411 1,746
OPM % 18% 11% 11% 8% 9% 20% 23% 30% 21% 29% 27% 34% 39%
16 6 15 17 55 28 26 23 31 38 33 -22 49
Interest 25 20 18 31 29 16 15 11 13 14 18 20 34
Depreciation 131 130 138 134 146 140 149 145 290 141 146 153 208
Profit before tax 362 145 173 67 142 577 696 1,084 428 1,083 984 1,217 1,553
Tax % 110% 19% 14% 40% 16% 17% 21% 15% 10% 18% 18% 19% 17%
-36 117 149 40 119 477 549 916 384 889 808 985 1,291
EPS in Rs -0.79 2.58 3.27 0.89 2.62 10.48 12.05 20.13 8.43 19.50 17.71 21.58 28.28
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
8,939 9,752 11,344 12,626 10,081 11,356 11,026 11,056 11,772 11,259 14,666 16,968
6,016 6,375 7,357 8,134 7,992 8,504 9,116 9,012 11,560 10,295 11,216 11,495
Operating Profit 2,922 3,377 3,987 4,492 2,089 2,853 1,909 2,044 211 964 3,451 5,472
OPM % 33% 35% 35% 36% 21% 25% 17% 18% 2% 9% 24% 32%
405 177 187 82 128 -49 -286 129 215 210 115 97
Interest 21 5 24 29 33 35 53 41 73 98 56 84
Depreciation 168 337 306 366 390 426 519 503 514 548 725 648
Profit before tax 3,139 3,212 3,844 4,179 1,794 2,342 1,052 1,630 -162 527 2,785 4,837
Tax % 26% 25% 26% 25% 25% 34% 31% 23% 17% 19% 16% 18%
2,324 2,397 2,831 3,141 1,345 1,539 728 1,259 -189 425 2,326 3,973
EPS in Rs 51.84 53.34 62.83 69.56 29.74 34.01 16.06 27.74 -4.15 9.35 51.05 87.02
Dividend Payout % 12% 14% 12% 11% 17% 15% 37% 23% -96% 43% 16% 14%
Compounded Sales Growth
10 Years: 6%
5 Years: 9%
3 Years: 13%
TTM: 16%
Compounded Profit Growth
10 Years: 5%
5 Years: 28%
3 Years: 173%
TTM: 75%
Stock Price CAGR
10 Years: 1%
5 Years: 17%
3 Years: 49%
1 Year: 21%
Return on Equity
10 Years: 11%
5 Years: 8%
3 Years: 11%
Last Year: 18%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 90 90 90 90 90 90 91 91 91 91 91 91
Reserves 6,889 8,938 11,823 14,690 15,695 17,027 17,383 18,475 18,059 18,321 20,512 24,187
144 45 392 593 17 6 6 485 951 749 105 250
1,675 1,935 1,931 2,475 2,879 2,567 3,201 2,808 3,212 3,523 4,215 3,904
Total Liabilities 8,799 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923 28,432
2,179 2,036 2,345 3,013 3,341 3,373 3,514 3,639 3,690 4,022 4,113 4,992
CWIP 267 490 624 481 1,171 1,199 822 951 947 927 446 232
Investments 1,164 3,444 3,741 6,914 5,363 7,388 7,456 9,563 9,511 9,974 11,581 11,955
5,189 5,038 7,526 7,441 8,806 7,730 8,888 7,706 8,165 7,761 8,783 11,253
Total Assets 8,799 11,008 14,236 17,848 18,681 19,690 20,680 21,859 22,313 22,684 24,923 28,432

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1,528 2,852 917 4,352 209 3,111 2,219 1,570 151 1,794 2,504 2,445
-447 -1,178 -2,629 -1,941 725 -2,865 -740 -2,508 -372 -1,269 -1,599 -1,766
-844 -221 17 -160 -987 -295 -368 -53 102 -498 -867 -460
Net Cash Flow 237 1,452 -1,696 2,252 -52 -50 1,112 -991 -118 27 38 218

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 117 94 146 113 179 120 120 105 84 87 96 122
Inventory Days 174 211 214 232 229 216 216 236 260 230 216 239
Days Payable 124 126 126 161 150 118 136 104 110 119 148 146
Cash Conversion Cycle 166 179 234 184 258 218 199 237 234 197 163 215
Working Capital Days 138 116 181 144 219 171 154 158 151 132 117 176
ROCE % 50% 40% 36% 30% 11% 16% 10% 9% -1% 3% 14% 22%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
47.10% 47.11% 47.10% 47.08% 47.07% 47.06% 47.04% 47.01% 46.99% 46.96% 46.94% 46.91%
14.27% 13.81% 13.98% 13.32% 13.93% 14.99% 16.11% 18.29% 19.32% 21.50% 22.04% 21.46%
26.89% 27.63% 29.39% 28.92% 29.08% 29.14% 29.72% 27.76% 26.77% 25.10% 24.73% 25.41%
0.29% 0.00% 0.00% 0.28% 0.28% 0.28% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
11.45% 11.45% 9.51% 10.39% 9.62% 8.52% 7.10% 6.93% 6.92% 6.44% 6.27% 6.21%
No. of Shareholders 3,82,8283,78,0113,60,6773,48,1493,22,6782,89,0742,81,5422,80,2482,88,5372,79,2802,81,9882,83,210

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls